Who are combination with dopamine agonist cabergoline's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cabergoline Pill, Abilify Maintena, paliperidone clozapine, ropinirole CR-RLS, Flupentixol melitracen tablets, Raclopride C11.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/combination-with-dopamine-agonist-cabergoline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

combination with dopamine agonist cabergoline — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

combination with dopamine agonist cabergoline (combination with dopamine agonist cabergoline) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine agonist. Area: Endocrinology.

marketed Dopamine agonist Dopamine D2 receptor Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

combination with dopamine agonist cabergoline (combination with dopamine agonist cabergoline) — Ludwig-Maximilians - University of Munich. Cabergoline is a dopamine agonist that stimulates dopamine D2 receptors to inhibit prolactin secretion from the anterior pituitary gland.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
combination with dopamine agonist cabergoline TARGET	combination with dopamine agonist cabergoline	Ludwig-Maximilians - University of Munich	marketed	Dopamine agonist	Dopamine D2 receptor
Cabergoline Pill	Cabergoline Pill	Fertility Center of Las Vegas	marketed	Dopamine D2 receptor agonist	Dopamine D2 receptor
Abilify Maintena	Abilify Maintena	Gazda, Thomas D., M.D., PC	marketed	Atypical antipsychotic	Dopamine D2 receptor (partial agonist); serotonin 5-HT1A receptor
paliperidone clozapine	paliperidone clozapine	Universidad Nacional de Rosario	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
ropinirole CR-RLS	ropinirole CR-RLS	GlaxoSmithKline	marketed	Dopamine D2/D3 receptor agonist	Dopamine D2 receptor, Dopamine D3 receptor
Flupentixol melitracen tablets	Flupentixol melitracen tablets	Peking University Third Hospital	marketed	Typical antipsychotic + tricyclic antidepressant combination	Dopamine D2 receptor (flupentixol); norepinephrine and serotonin transporters (melitracen)
Raclopride C11	Raclopride C11	University of North Carolina, Chapel Hill	marketed	Dopamine D2/D3 receptor antagonist (PET imaging agent)	Dopamine D2 receptor, Dopamine D3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine agonist class)

Sumitomo Pharma America, Inc. · 2 drugs in this class
University Hospital, Toulouse · 2 drugs in this class
Rennes University Hospital · 2 drugs in this class
Britannia Pharmaceuticals Ltd. · 1 drug in this class
Desitin Arzneimittel GmbH · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Intec Pharma Ltd. · 1 drug in this class
Leiden University Medical Center · 1 drug in this class
Ludwig-Maximilians - University of Munich · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). combination with dopamine agonist cabergoline — Competitive Intelligence Brief. https://druglandscape.com/ci/combination-with-dopamine-agonist-cabergoline. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab